TVGN TEVOGEN BIO HOLDINGS INC

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today informed shareholders about several differences between holding shares in Direct Registration System (“DRS”) accounts and holding them in brokerage accounts.

A DRS account is an alternative to using a brokerage account and Tevogen encourages shareholders to explore the differences. DRS accounts ensure your shares are registered directly in your name and not held through intermediary brokers, allowing shareholder to exercise direct control over their shares. DRS accounts may also have reduced transaction and account maintenance costs for shareholders. Brokerage accounts may provide greater access to tools, and selling shares in this type of account may be quicker when compared to a DRS account. Investors may also incur certain costs in connection with transferring shares in and out of a brokerage account.

For more information about these and other differences, please contact the Company’s transfer agent, Continental Stock Transfer & Trust.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
29/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges w...

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ). As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare. With the concern of Chinese pharmaceutical companies developing drugs at a faster pace and lower cost, the U.S. biotech sector faces p...

 PRESS RELEASE

Tevogen to Share Direct Registration System (DRS) Process Details Foll...

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account. In response, Tevogen will provide step-by-step guidance early next week to help interested s...

 PRESS RELEASE

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manuf...

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of intent for a facility designed to support Tevogen Bio’s cell therapy manufacturing facility. Tevogen Founder and CEO, Ryan Saadi, MD, MPH commented, “In-house manufacturing is critical to our operational efficiency, and with 74% insider ownership, we place the highest ...

 PRESS RELEASE

Tevogen Informs Public Shareholders About DRS Accounts And Differences...

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today informed shareholders about several differences between holding shares in Direct Registration System (“DRS”) accounts and holding them in brokerage accounts. A DRS account is an alternative to using a brokerage account and Tevogen encourages shareholders to explore the differences. DRS accounts ensure your shares are registered directly in your name and not held through intermediary brok...

 PRESS RELEASE

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Ada...

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in . Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at . Along with Dr. Ryan Saadi, the panel will als...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch